# Diabetes Research Hub — Monitor Report

**Generated:** 2026-05-15 (automated scheduled run)
**Scan window:** since previous monitor report (2026-05-14)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`

---

## 1. File System Status

| File | Last Modified | Age | Status |
|---|---|---|---|
| `Analysis/Results/hub_monitor_report.md` | 2026-05-14 07:05 | 1d | OK |
| `Analysis/Results/clinical_trials_latest.json` | 2026-05-14 07:04 | 1d | OK |
| `Analysis/Results/clinical_trials_snapshot_2026-05-14.json` | 2026-05-14 | 1d | OK (latest daily snapshot) |
| `Analysis/Results/pubmed_recent_latest.json` | 2026-05-14 07:05 | 1d | OK |
| `Analysis/Results/pubmed_recent_snapshot_2026-05-14.json` | 2026-05-14 | 1d | OK |
| `Analysis/Results/literature_gap_report.md` | 2026-05-13 14:19 | 2d | OK |
| `Analysis/Results/literature_gap_data.json` | 2026-04-20 10:35 | **25d** | **STALE (>14d) — re-run recommended** |
| `Analysis/Results/agent_state.json` | 2026-05-13 14:20 | 2d | OK |
| `Research_Findings_Summary.md` | 2026-05-13 14:20 | 2d | OK |
| `Diabetes_Research_Tracker.xlsx` | 2026-04-17 14:50 | **28d** | **STALE — manual refresh due** |

### Notes on file status

The user's daily Python scripts have **not been run yet today (2026-05-15)** — no `clinical_trials_snapshot_2026-05-15.json`, `pubmed_recent_snapshot_2026-05-15.json`, or refreshed `hub_monitor_report.md` exist as of this scan. All "latest" feeds are therefore unchanged since the 2026-05-14 run, so the trial/PubMed deltas in this report are identical to yesterday's. Recommend running the daily scripts (see Recommended Actions §6).

The previous `hub_monitor_report.md` (last run 2026-05-14 07:05) tracked **3 new files / 29 modified files / 0 removed** versus 2026-05-13 and flagged **563 result files older than 14 days**.

---

## 2. Clinical Trial Status

**Universe:** 793 tracked trials (T1D cell therapy 152 · T1D immunotherapy 72 · T2D novel 140 · Devices 221 · Recently completed w/ results 280).

**Status mix:** RECRUITING 266 · NOT_YET_RECRUITING 131 · ACTIVE_NOT_RECRUITING 110 · ENROLLING_BY_INVITATION 6 · COMPLETED 280.

**Phase mix:** PHASE3 122 · PHASE2 125 · PHASE2/3 16 · PHASE4 23 · PHASE1 13 · NA/N/A 465.

### Δ vs. last monitor cycle (2026-05-14)
No new data ingested since yesterday's run. The deltas captured in yesterday's report remain the most current trial-side news:

- **NCT05514535** (Novo Nordisk PHASE 3 — semaglutide + lower-dose insulin glargine in T2D) — **COMPLETED, results posted 2026-05-11**. Still the top items to review for tracker entry.
- **NCT04333823** (Adolescent T1D + SGLT2i, SickKids) — newly indexed Phase 3 / ACTIVE_NOT_RECRUITING.
- **NCT07379333** (HM11260C / efpeglenatide-class long-acting GLP-1) — status moved NOT_YET_RECRUITING → RECRUITING.
- **NCT05454891** (UCSF — extended bolus for meals in closed-loop AID) — results posted 2026-05-12.

### Phase 3 / Recruiting — Priority Watch List (unchanged)
46 Phase 3 trials are currently recruiting across the corpus. Priority watch:

| NCT ID | Sponsor | Therapy / Focus | Why It Matters |
|---|---|---|---|
| NCT04786262, NCT06832410 | Vertex | VX-880 / zimislecel (T1D islet cell) | Tier 3 cell therapy with continued positive readouts (see §5) |
| NCT07088068 | Sanofi/Provention | Teplizumab Phase 3 (T1D) | Still RECRUITING; pairs with 2026-04-22 FDA pediatric expansion |
| NCT07222137, NCT07222332 | Eli Lilly | Baricitinib Phase 3 (delay Stage 3 T1D) | Active, important T1D immunotherapy line |
| NCT06962280 | Eli Lilly | Tirzepatide T1D long-term | ACTIVE_NOT_RECRUITING — watch for primary completion |

### Recently posted results to triage (last 30 days)
- 2026-05-11 NCT05514535 (Novo Nordisk Phase 3, semaglutide + glargine, T2D) — **highest priority**.
- 2026-05-12 NCT05454891 (Closed-loop AID extended-bolus) — relevant to Closed Loop AP.
- 2026-05-04 NCT03940209 (Addressing basic needs to improve diabetes outcomes, Medicaid) — Phase 2, equity-relevant.

---

## 3. PubMed Highlights

**Snapshot:** 145 unique papers across 16 alert domains (30-day lookback, generated 2026-05-14).

### Domain activity (last 30d, unchanged since yesterday)
- **High volume:** Diabetes AI/ML 199 · Diabetes Biomarker 151 · T2D GLP-1 New 143 · Diabetes Microbiome 122 · T2D Remission 68.
- **Low volume (notable):** T1D Stem Cell 20 · T1D Immunotherapy 17 · Closed Loop AP 16 · Diabetes Epigenetics 7 · Drug Repurposing 6 · LADA 5 · GLP-1 Pharmacogenomics 1.

The persistent very-low LADA and GLP-1-pharmacogenomics signals continue to align with the standing literature-gap findings (Section 4).

### Cross-Domain Papers — Highest Priority
13 cross-domain hits in the latest pull. Top actionables:

| PMID | Date | Title (truncated) | Domains |
|---|---|---|---|
| 42051156 | 2026-04-29 | BDA/ABCD Consensus — clinical use of teplizumab in Stage 2 T1D | T1D Immunotherapy · Key therapy: teplizumab |
| 42128231 | 2026-05-12 | GLP-1RA-like effects of Bafetinib (in vitro + in vivo) | T2D GLP-1 · **Drug Repurposing** |
| 42104727 | 2026-05-09 | Stem-cell therapies for T1D — differentiation, translation, immune protection | T1D Stem Cell · Gene Therapy |
| 42108331 | 2026-05-11 | Automated insulin delivery in advanced CKD (Diabetologia) | T2D Remission · Closed Loop AP |
| 42123550 | 2026-04-29 | Operon™ platform — cardiometabolic biomarker screening | Biomarker · Microbiome · Multi-Omics |
| 42129562 | 2026-05-13 | Sleep chart of biological ageing clocks (Nature) | AI/ML · Multi-Omics |
| 42089665 | 2026-05-06 | VEGFA-targeted ionizable LNPs for diabetic retinopathy | Gene Therapy · Complications |

### Key Therapy Mentions (30-day window, abstract-level)
| Therapy | Papers (30d) | Notable |
|---|---|---|
| dapagliflozin | 27 | Multiple cardiorenal mechanism / outcome papers |
| **orforglipron** | 6 | PMID 42120723 (Phase 3b ATTAIN-MAINTAIN, Nature Medicine, 2026-05-13); PMID 42116665 (GI safety meta-analysis) |
| icodec | 4 | PMID 42119975 (T1D+T2D pooled safety, ONWARDS 1-6) |
| **teplizumab** | 3 | PMID 42051156 (**BDA Consensus**); 41796109 & 41535597 (real-world adult data) |
| retatrutide | 2 | PMID 42108533 (CKM review of triple-agonism) — note Phase 3 topline today (§5) |
| baricitinib | 2 | Non-diabetes case reports |
| zimislecel | 0 | No PubMed indexing yet — Vertex output still flowing through congress/press channels |
| CagriSema | 0 | No 30-day activity |

---

## 4. Gap Analysis Summary

The gap **report markdown** is current (regenerated 2026-05-13), but the underlying **`literature_gap_data.json` is 25 days old (2026-04-20)** and should be re-run.

### Top 5 Ranked Gaps (Bronze validation level)
1. **Beta Cell Regen × Health Equity** — gap 100, 0 joint pubs.
2. **Insulin Resistance × Islet Transplant** — gap 100, 1 joint pub.
3. **Islet Transplant × Drug Repurposing** — gap 100, 0 joint pubs.
4. **Islet Transplant × Health Equity** — gap 100, 0 joint pubs.
5. **Gene Therapy × LADA** — gap 100, 0 joint pubs.

(Pair #3 in the prior report — Islet Transplant × GWAS/Polygenic — is classified methodologically distinct and deprioritized.)

### Alignment with Tier 1 Doctrine Areas
- **Drug Repurposing × Islet / Drug Repurposing × LADA** sit inside Tier 1 #4 (Drug Repurposing Computational Screening). PMID 42128231 (Bafetinib → GLP-1RA-like activity) is a fresh concrete instance — the second such repurposing signal in two weeks.
- **Health Equity × Beta Cell Regen / Islet Transplant / Treg-CAR-T** spans Tier 1 #6 (Epidemiology). Access-equity analysis of advanced cell/immune therapies remains a wide-open lane.
- **Islet Transplant × Insulin Resistance** intersects Tier 1 #1 (Multi-Omics Biomarker Integration) if framed via post-transplant metabolic phenotyping.

---

## 5. Breaking News (Web Verified, Last 7 Days)

Genuinely new since the 2026-05-14 monitor cycle:

- **NEW (2026-05-14) — Eli Lilly TRANSCEND-T2D-1 Phase 3 topline (retatrutide).** Triple GIP/GLP-1/glucagon agonist hit primary endpoint over 40 weeks: A1C reduction **1.7–2.0%** across doses; 12 mg arm produced **~16.8% body-weight loss (~36.6 lb)**. Full data reserved for ADA 2026 Scientific Sessions in June + peer-reviewed publication. **Tier-1 relevance:** this is the first Phase 3 readout for the triple-agonist class in T2D and is the strongest single therapy headline this cycle. *(Evidence: Gold once cross-referenced with Lilly investor release; Silver as of this run.)*
- **NEW (2026-05-13) — Novo Nordisk OASIS 4 (oral semaglutide 25 mg) sub-analyses at ECO 2026.** 28.8% of adults were early responders (≥10% weight loss by week 16); responders averaged 21.6% weight loss by week 64. Reinforces oral-GLP-1 momentum alongside Lilly orforglipron. *(Silver.)*
- **CONFIRMED (2026-04-29 → still trending) — Langlara (insulin glargine-aldy)** interchangeable biosimilar to Lantus, FDA approved. Cost-access implication for basal insulin.
- **CONFIRMED — Eli Lilly orforglipron / "Foundayo™" FDA approval** (oral GLP-1 weight loss). Pairs directly with PMID 42120723 (ATTAIN-MAINTAIN, Nature Medicine, 2026-05-13).
- **CONFIRMED — Sanofi Tzield (teplizumab) pediatric expansion** (Stage 2 → delay Stage 3, ages 1+). Pairs with BDA Consensus PMID 42051156.
- **CONFIRMED — Vertex zimislecel NEJM publication / ADA 85 presentation:** 12/12 evaluable participants free of severe hypoglycemia, all <7% A1c, 10/12 (83%) insulin-independent at 1 year. *(Silver/Gold across NEJM + ADA + Vertex press.)*

Items deliberately skipped: routine country-level Ozempic launches, generic dapagliflozin approvals (already noted prior cycle), individual case reports.

---

## 6. Recommended Actions

Prioritized for this cycle:

1. **Run the daily ingest scripts** — no 2026-05-15 outputs yet exist:
   - `python hub_monitor.py`
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
2. **Add retatrutide TRANSCEND-T2D-1 topline (2026-05-14)** to Research_Findings_Summary.md and the GLP-1/Multi-Agonist row of the tracker — this is the most consequential single new datapoint since yesterday's run. Verify with Lilly investor release before stamping as Gold.
3. **Add OASIS 4 oral-semaglutide sub-analyses (ECO 2026, 2026-05-13)** to the GLP-1 New section.
4. **Update tracker with the Novo Nordisk Phase 3 result NCT05514535** (semaglutide + low-dose glargine, results 2026-05-11) — carried over from yesterday's recommended actions; still pending.
5. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. `literature_gap_data.json` is now 25 days old.
6. **Re-review Drug Repurposing × Islet / × LADA** in light of PMID 42128231 (Bafetinib GLP-1RA-like effect) — second repurposing signal in two weeks; this is a Tier 1 contribution area.
7. **Diabetes_Research_Tracker.xlsx is 28 days old** — schedule the manual sync that was queued yesterday.
8. **Flag for next cycle:** if Vertex announces a Phase 3 zimislecel update (currently no PubMed indexing despite NEJM/ADA presence), capture into the T1D Stem Cell domain manually rather than waiting for PubMed.

---

## 7. Evidence-Level Tags

Per the Research Doctrine, claims surfaced in this report carry the following levels:

- ClinicalTrials.gov / PubMed-indexed status changes: **Silver** (single authoritative source, public registry).
- New FDA approvals (press release + cross-confirmed): **Gold** once cross-referenced with Drugs@FDA listing — **Silver** until verified in this run.
- Phase 3 topline readouts from company press releases (retatrutide, OASIS 4): **Silver / awaiting peer-reviewed publication** — do not treat as Gold until full data are public.
- Cross-domain PubMed hits: **Bronze** until at least one independent replication is in hand.
- Gap-analysis rankings: **Bronze** (single bibliometric source).
- Preclinical animal-only items: **Bronze / preclinical**.

---

*Run produced autonomously by the diabetes-hub-monitor scheduled task. No source files were modified.*
